Fused bicyclic RAF inhibitors and methods for use thereof

Inventors

BELFIELD, Andrew • Jones, Clifford David • MARGATHE, Jean-François • COLLETTO, Chiara

Assignees

Redx Pharma Ltd • Jazz Pharmaceuticals Ireland Ltd

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12304912-B2

Patent

Publication Date

2025-05-20

Expiration Date


Abstract

The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitors of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The disclosure also relates to method of using the compound of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, for treating diseases such as cancer, including colorectal cancer.

Core Innovation

The invention is directed to compounds of formula (II), including pharmaceutically acceptable salts, tautomers, and stereoisomers. The formula includes defined values for X1 and X2, where X1 and X2 are each N or CH, and substitution patterns for R1 and R4. R1 is selected from substituted C1-8 alkyl, unsubstituted C5-8 alkyl, substituted or unsubstituted C1-8 haloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, or substituted or unsubstituted heteroaryl.

In the compounds of formula (II), the linker group R4 is specified by one of several amide-related patterns: —NRF C(O)R5, —NRF C(O)CH2R5, —NRF C(O)CH(CH3)R5, or —NRF R5. The variable substituent R5 is selected from alkyl, carbocyclyl, aryl, heterocyclyl, or heteroaryl, and the variable group RF is H or C1-3 alkyl. The disclosed embodiments include examples with specific substituents and stereoisomer/racemate status.

The compounds are described as RAF inhibitors intended for inhibiting RAF kinases in the RAS-RAF-MAPK pathway, including A-RAF, B-RAF, and C-RAF. The therapeutic intent described is treatment of conditions modulated by RAF kinase, including cancer, with emphasis on BRAF V600E mutation cancers such as melanoma and colorectal cancer. The document further covers pharmaceutical compositions containing the compounds with pharmaceutically acceptable excipients or carriers, and optionally including additional therapeutic agents.

Claims Coverage

The independent claim coverage centers on a compound of formula (II) with specified structural variables X1, X2, R1, R4, R5, and RF, and explicit coverage for pharmaceutically acceptable salts, tautomers, and stereoisomers. The inventive features merge a defined scaffold with constrained substituent options and extend to pharmaceutical compositions and cancer treatment subtypes.

Formula (II) compound scaffold

A compound of formula (II), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein X1 and X2 are each N or CH.

Defined R1 substituent classes

R1 is a substituted C1-8 alkyl, an unsubstituted C5-8 alkyl, a substituted or unsubstituted C1-8 haloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heterocyclyl, or a substituted or unsubstituted heteroaryl.

Amide-related R4 substituent patterns

R4 is —NRF C(O)R5, —NRF C(O)CH2R5, —NRF C(O)CH(CH3)R5, or —NRF R5.

Defined R5 and RF selection

R5 is a substituted or unsubstituted group selected from alkyl, carbocyclyl, aryl, heterocyclyl, or heteroaryl, and RF is H or C1-3 alkyl.

Pharmaceutical composition with excipient or carrier

A pharmaceutical composition comprising a compound of formula (II) and a pharmaceutically acceptable excipient or carrier.

BRAF V600E cancer treatment subtypes

A method of treating cancer wherein the cancer is BRAF V600E melanoma or BRAF V600E colorectal cancer.

Overall, the claim set is defined by the formula (II) scaffold with X1/X2 limited to N or CH, R1 limited to specified alkyl/haloalkyl/aryl/heterocycle/heteroaryl classes, and R4 defined by specific RF- and R5-containing patterns, with RF restricted to H or C1-3 alkyl. Dependent coverage adds pharmaceutical composition and treatment of BRAF V600E melanoma and BRAF V600E colorectal cancer.

Stated Advantages

Not explicitly described in patent.

Documented Applications

Treatment of conditions modulated by RAF kinase, including cancer.

Treatment of BRAF V600E melanoma.

Treatment of BRAF V600E colorectal cancer.

Cell-based evaluation using AlphaLISA SureFire pERK1/2 assays and 3D CellTiter-Glo proliferation assays.

In vitro ADME-type measurements including microsomal stability, plasma protein binding, and FeSSIF solubility.

Chiral separation using preparative SFC for chiral forms of example compounds.

Methods of treating cancer where the cancer is BRAF V600E melanoma or BRAF V600E colorectal cancer.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.